Compare CSGS & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSGS | AAPG |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1996 | N/A |
| Metric | CSGS | AAPG |
|---|---|---|
| Price | $80.69 | $20.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $77.23 | $48.40 |
| AVG Volume (30 Days) | ★ 308.4K | 2.5K |
| Earning Date | 05-11-2026 | 05-20-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $996,810,000.00 | N/A |
| Revenue This Year | $5.45 | $290.34 |
| Revenue Next Year | $3.02 | N/A |
| P/E Ratio | $97.23 | ★ N/A |
| Revenue Growth | ★ 13.91 | N/A |
| 52 Week Low | $60.54 | $20.01 |
| 52 Week High | $80.73 | $48.45 |
| Indicator | CSGS | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 70.19 | 32.39 |
| Support Level | $80.13 | $20.11 |
| Resistance Level | N/A | $25.23 |
| Average True Range (ATR) | 0.19 | 0.51 |
| MACD | 0.02 | -0.22 |
| Stochastic Oscillator | 93.62 | 13.54 |
CSG Systems International Inc is a purpose-driven, SaaS platform company that enables companies in a wide variety of industry verticals to tackle the growing complexity of business in the digital age. The company's cloud-first architecture and customer-centric approach empower companies to deliver unforgettable experiences for B2B (business-to-business), B2C (business-to-consumer), and B2B2X (business-to-business-to-consumer) customers, making it easier for people and businesses to connect to, use and pay for the services the company offers. The company operates in one segment i.e. Solutions and Services. Geographically, it generates revenue from the United States.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.